Clinical Trials Logo

Clinical Trial Summary

The study will be a randomized double blind prospective placebo controlled clinical study and aims to determine the therapeutic efficacy of Probiotics in Oral Mucositis pathogenesis in patients undergoing head and neck radiotherapy.


Clinical Trial Description

The study will be a randomized double blind prospective placebo controlled clinical study (Clinical Trial phase II) of 50 patients (25 in LR group, 25 in placebo group) with a confirmed cancer diagnosis requiring head and neck radiotherapy with a minimum dose of 6000cGy.

Patients will be randomly assigned to either of the treatment arms in a 1:1 ratio. The active agent; Lactobacillus reuteri Prodentis (Biogaia ®) will be supplied in droplet form by Pharma forte Singapore Pte Ltd and dosage used will be as recommended by manufacturer (5 drops/time twice a day which is equivalent to 4 X 108 CFU of live bacteria). The control agent will be identical in physical appearance and color to the study agent and will be made by the manufacturer.

Patients assigned to either LR group or placebo group will start from the first day of radiotherapy and continued until 2-week post radiation (approximately 8-9 weeks). Patients will be instructed to use the LR droplets twice a day according to manufacturer's instructions; once in the morning after breakfast and the other just before bedtime and to avoid any food/drinks 30 minutes before and after usage. Compliance with treatment will be elicited and recorded.

The dose selection is based on manufacturer's recommendations and is safe for use during pregnancy and breastfeeding. However, this is not an issue in this population as none of the patients should be pregnant or breastfeeding while receiving radiation and anti-neoplastic chemotherapy.

The PI will serve as the auditor for data quality assurance on a quarterly basis.Data collected on paper will be stored in the principal investigator's locked cabinet. Data will be entered into Microsoft Excelâ„¢ (2007) and double entered for accuracy. Data will be kept in a password secured portable computer and backed up to dedicated local back-up drive every week. Only group statistics will be reported. The database will only be accessible to investigators involved in and approved for the study. All data will be kept for 6 years after study completion to access data for publication of the work done, after which data will be destroyed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03552458
Study type Interventional
Source National University Hospital, Singapore
Contact Catherine Hong, Master
Phone 65-6779 5555
Email denchhl@nus.edu.sg
Status Recruiting
Phase Phase 2
Start date June 26, 2018
Completion date June 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04607694 - DAHANCA 35: Proton Versus Photon Therapy for Head-neck Cancer N/A
Active, not recruiting NCT05423704 - Feasibility of Patient Selection and Treatment of Head-neck Cancer With Proton Therapy in Denmark N/A
Completed NCT02776137 - Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck Phase 2
Recruiting NCT02238587 - The Effect of Ganoderma on Patients With Head-and-neck Cancer N/A
Enrolling by invitation NCT04257968 - Long Term Complications in Head and Neck Cancer Patients N/A
Recruiting NCT02764216 - Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary Phase 2